Multiplex Microsphere Assay for Soluble FGFR Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting soluble fibroblast growth factor receptors (sFGFRs) in biological samples are not sensitive, linear, or diagnostic, and existing assays are unsatisfactory for detecting sFGFR2, sFGFR3, and sFGFR4, necessitating the development of a standardized, fast, precise, and economical screening method.
Innovation Solution
A multiplex microsphere-based platform using capture and detection antibodies specifically binding to sFGFR2, sFGFR3, and sFGFR4, conjugated to microspheres and detection labels, respectively, to detect predefined threshold levels of these receptors in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used for sFGFRs, then the assay can be performed with simple equipment, but the sensitivity and diagnostic accuracy are insufficient
Solution Approach 1:
The patent combines multiple detection functions into a single multiplex assay platform using microspheres with spectral addressing. Different capture antibodies specific to sFGFR2, sFGFR3, and sFGFR4 are conjugated to distinct microsphere sets that can be simultaneously detected using a single instrument with multiple lasers, achieving high sensitivity without proportionally increasing device complexity
Solution Approach 2:
The invention creates a universal detection platform that can measure multiple soluble FGFR isoforms (sFGFR2, sFGFR3, sFGFR4) simultaneously in a single assay. The system uses a panel of capture antibodies and detection antibodies that work together across different microsphere sets, allowing one instrument to perform multiple detection functions
2Reliability
If existing assays are used to detect sFGFR2, sFGFR3, and sFGFR4, then the methodology is established, but the detection is unsatisfactory and not standardized
Solution Approach 1:
The patent performs preliminary optimization of antibody concentrations, microsphere-to-antibody ratios, and assay buffer compositions during the kit manufacturing process. Capture antibodies are pre-conjugated to specific microsphere sets with optimized densities, and detection antibodies are pre-formed with detection labels, ensuring consistent and reliable detection across all assays performed with the kit
Solution Approach 2:
The invention establishes standardized parameter ranges for assay performance including microsphere concentration, antibody concentrations, incubation times, and detection thresholds. These standardized parameters are built into the kit protocol, making the assay reliable and reproducible while simplifying manufacturing and quality control
3Measurement precision
If a multiplex microsphere-based platform is implemented, then detection sensitivity and specificity are improved, but the device complexity increases
Solution Approach 1:
The patent uses microspheres with spectral addressing as intermediaries between the sample containing multiple sFGFR isoforms and the detection system. Each microsphere set acts as a unique identifier and signal amplifier for its specific capture antibody, enabling simultaneous quantification of multiple analytes with high precision while managing complexity through standardized spectral codes
Solution Approach 2:
The invention replaces traditional sequential detection methods with a parallel optical detection system using fluorescence spectroscopy. Multiple lasers excite different fluorophores on different microsphere sets simultaneously, and detectors measure emitted light at specific wavelengths, substituting mechanical/chemical separation steps with optical discrimination for higher throughput and accuracy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the accurate detection and quantification of sFGFR2, sFGFR3, and sFGFR4 in biological samples, providing a basis for identifying and quantifying FGF content in oncology patients, with improved sensitivity and specificity compared to previous methods.
Implementation Method 1
a capture antibody composition specifically binding sFGFRs conjugated to the microsphere
Implementation Method 2
a detection antibody composition specifically binding sFGFRs conjugated to a detection label
Implementation Method 3
measuring the signal produced by the detection label; correlating the amount of the signal produced to the amount of sFGFR2, sFGFR3 or sFGFR4
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided are kits and methods for measuring and detecting soluble fibroblast growth factor receptors (sFGFRs) 2, 3 and 4 in a biological sample, using multiplexing microsphere technology.